Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Average Rating of “Hold” by Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been given an average rating of “Hold” by the eleven analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $42.5556.

A number of research analysts have recently commented on AGIO shares. Wall Street Zen upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. Royal Bank Of Canada raised their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. JPMorgan Chase & Co. dropped their target price on shares of Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a research report on Thursday, June 11th. Truist Financial upped their target price on shares of Agios Pharmaceuticals from $36.00 to $41.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Finally, Bank of America increased their price target on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 7th.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $39.87 on Thursday. The business’s 50-day simple moving average is $32.56 and its 200-day simple moving average is $30.18. The firm has a market capitalization of $2.37 billion, a PE ratio of -5.50 and a beta of 0.54. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, topping the consensus estimate of ($1.81) by $0.12. The business had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $13.30 million. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The business’s quarterly revenue was up 137.7% compared to the same quarter last year. Research analysts forecast that Agios Pharmaceuticals will post -6.32 earnings per share for the current year.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP increased its position in shares of Agios Pharmaceuticals by 485.5% during the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after purchasing an additional 2,049,287 shares during the period. MPM Bioimpact LLC bought a new position in Agios Pharmaceuticals in the fourth quarter worth $35,478,000. State Street Corp lifted its position in Agios Pharmaceuticals by 37.4% in the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after purchasing an additional 845,433 shares during the period. TCG Crossover Management LLC boosted its stake in Agios Pharmaceuticals by 105.2% during the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock worth $57,402,000 after buying an additional 733,038 shares in the last quarter. Finally, Capital International Investors acquired a new stake in Agios Pharmaceuticals during the fourth quarter worth $19,159,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.